United Therapeutics (UTHR) Stock: Charts & Financials

United Therapeutics Corporation (UTHR)UTHRUnited Therapeutics Corporation

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1UTHR	$22.29B	$525.05	+0.27%	+75.70%	+23.07%	+15.97%	N/A
2STE	$22.70B	$232.97	+1.14%	+2.77%	+2.43%	+13.80%	vs UTHR
3MRNA	$21.82B	$54.99	-1.46%	+64.64%	-30.71%	N/A	vs UTHR
4BNTX	$23.74B	$93.88	+1.55%	-18.04%	-21.46%	N/A	vs UTHR
5WST	$23.83B	$338.64	+0.49%	+31.20%	-2.33%	+15.88%	vs UTHR
6VTRS	$20.62B	$17.71	-0.84%	+100.45%	+9.14%	-7.18%	vs UTHR

Period	Low	Avg	High	# Analysts
Quarter ending Jun 2026	$6.28	$7.06	$7.74	8
Quarter ending Sep 2026	$6.24	$7.21	$7.67	9
Quarter ending Dec 2026	$6.88	$7.27	$7.85	7
Quarter ending Mar 2027	$7.36	$7.77	$8.39	3

Period	Low	Avg	High	# Analysts
FY 2026	$26.08	$27.87	$29.74	11
FY 2027	$25.48	$32.84	$39.99	11

Period	Low	Avg	High	# Analysts
Quarter ending Jun 2026	$790.36M	$804.65M	$830.38M	8
Quarter ending Sep 2026	$789.19M	$818.76M	$879.32M	8
Quarter ending Dec 2026	$799.19M	$832.94M	$884.16M	7
Quarter ending Mar 2027	$732.51M	$763.43M	$810.38M	4

FY 2026	$3.19B	$3.24B	$3.34B	10
FY 2027	$3.28B	$3.68B	$4.35B	11

United Therapeutics Corporation (UTHR) Stock Price: $525.05+1.42 (+0.27%)

Business at a glance

UTHR Price Chart

Compounder charts

UTHR is featured in

UTHR Key Metrics

Total Return CAGR

UTHR Fundamental Charts

Revenue CAGR

Net Income CAGR

EPS CAGR

Operating Cash Flow CAGR

Free Cash Flow CAGR

EBITDA CAGR

UTHR Revenue by Segment

By product / business (FY 2025)

UTHR Earnings Preview

Similar-Size Sector Stocks

UTHR Competitors' Key Metrics

UTHR Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

By geography (FY 2025)

UTHR Analyst Ratings

UTHR Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates